The Latest Breaking News from Biogen

Expert Ratings For Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga · Mar 3, 2022

Inside the tactical tug of war over the controversial Alzheimer’s drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

Tribune News Service · Feb 17, 2022

Patients’ groups, progressives square off over Medicare Alzheimer’s decision

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Tribune News Service · Feb 15, 2022

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga · Feb 4, 2022

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Benzinga · Feb 4, 2022

Biogen's Return On Capital Employed Insights

Benzinga Pro data, Biogen (NASDAQ:BIIB) reported Q4 sales of $2.73 billion. Earnings fell to a loss of $20.50 million, resulting in a 106.44% decrease from last quarter. In Q3, Biogen earned $318.10 million, and total sales reached $2.78 billion.

Benzinga · Feb 4, 2022

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Benzinga · Feb 3, 2022

Biogen: Q4 Earnings Insights

  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 3, 2022

Why Biogen Shares Are Sliding Today

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates.

Benzinga · Feb 3, 2022

Biogen's 2022 outlook leaves investors wanting, shares slip

Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from  doctors and patient advocates

The Independent UK · Feb 3, 2022